Category
News
ISPE Pharma 4.0 2024
The new expansion at BioCork in Ireland has been recognised in two major international awards: It has received CURT Awards for both Project Excellence and Safety, and has been announced as ENR Global Projects Manufacturing Category Award Winner for 2024.
Do you have a pharmaceutical project? Talk to one of our experts.
Pharmaceutical Sector Director
BioCork is Johnson & Johnson Innovative Medicine’s state-of-the-art facility producing immunology and oncology treatments. PM Group has supported the design and build of the 20,000+ sqm campus in Ireland since 2005.
The latest project, BioCork3.2, is a 2,000 sq.m expansion. It facilitates multi-product manufacturing with increased capacity and a ‘Fed Batch’ process. This was the third expansion project at the BioCork site and was carried out alongside a live production environment.
New technologies facilitated real-time, daily collaboration during the BioCork projects delivery:
All the BioCork facilities have been designed and constructed with sustainability as a guiding principal. The latest project, BioCork 3.2 has achieved the LEED BD+C New Construction v4 Silver Award.
Key sustainable metrics:
Services
PM Group has been involved on all three major development projects at this c.40 hectare site from its original establishment in 2005 as a greenfield facility to produces monoclonal antibody products. Located in Ringaskiddy Co. Cork, the facility incorporates perfusion cell culture and purification processes.
Our scope has included site evaluation, master-planning and permitting, architecture and engineering design, procurement, construction management support, commissioning/qualification/validation and LEED AP consulting services.
Previous Awards
The earlier 19,000 sqm expansion project (BioCork 2) was recognised with ENR and CURT awards in 2020, and was Overall Winner and Project Execution Winner in the ISPE Facility of The Year Awards, 2021.
Pharmaceutical Sector Director